Does the media prefer BHC or BLTE?

In the previous week, Belite Bio had 1 more articles in the media than Bausch Health Cos. MarketBeat recorded 5 mentions for Belite Bio and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.38 beat Belite Bio's score of 0.20 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BHC or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Bausch Health Cos' net margin of -10.12%. Lantheus' return on equity of 28.10% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Bausch Health Cos -10.12% -561.95% 6.31% Lantheus 17.69% 28.10% 14.35%

Does the media prefer BHC or LNTH?

In the previous week, Lantheus had 6 more articles in the media than Bausch Health Cos. MarketBeat recorded 10 mentions for Lantheus and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.38 beat Lantheus' score of 0.23 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, BHC or LQDA?

Bausch Health Cos has higher revenue and earnings than Liquidia. Bausch Health Cos is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch Health Cos $10.27B 0.21 $157M -$2.96 N/A Liquidia $158.32M 16.19 -$68.92M $1.37 20.91

Is BHC or LQDA more profitable?

Liquidia has a net margin of 30.74% compared to Bausch Health Cos' net margin of -10.12%. Liquidia's return on equity of 149.65% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Bausch Health Cos -10.12% -561.95% 6.31% Liquidia 30.74% 149.65% 36.30%

Does the media prefer BHC or LQDA?

In the previous week, Liquidia had 27 more articles in the media than Bausch Health Cos. MarketBeat recorded 31 mentions for Liquidia and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.38 beat Liquidia's score of 0.28 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liquidia 7 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer BHC or AMRX?

In the previous week, Bausch Health Cos had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 4 mentions for Bausch Health Cos and 2 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.51 beat Bausch Health Cos' score of 0.38 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BHC or DFTX?

In the previous week, Definium Therapeutics had 16 more articles in the media than Bausch Health Cos. MarketBeat recorded 20 mentions for Definium Therapeutics and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.38 beat Definium Therapeutics' score of 0.32 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Definium Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bausch Health Cos (BHC) Competitors

$5.80 +0.08 (+1.31%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$5.80 0.00 (-0.07%)

As of 10/2/2026 07:57 PM Eastern

Compare

BHC vs. BLTE, LNTH, LQDA, AMRX, and DFTX

Should you buy Bausch Health Cos stock or one of its competitors? Bausch Health Cos's main competitors and comparable companies include Belite Bio (BLTE), Lantheus (LNTH), Liquidia (LQDA), Amneal Pharmaceuticals (AMRX), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bausch Health Cos compare to Belite Bio?

Bausch Health Cos (NYSE:BHC) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Bausch Health Cos currently has a consensus target price of $8.00, indicating a potential upside of 37.81%. Belite Bio has a consensus target price of $218.73, indicating a potential upside of 37.08%. Given Bausch Health Cos' higher possible upside, analysts plainly believe Bausch Health Cos is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Belite Bio had 1 more articles in the media than Bausch Health Cos. MarketBeat recorded 5 mentions for Belite Bio and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.38 beat Belite Bio's score of 0.20 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bausch Health Cos has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.21	$157M	-$2.96	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Bausch Health Cos has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market.

Belite Bio has a net margin of 0.00% compared to Bausch Health Cos' net margin of -10.12%. Belite Bio's return on equity of -11.84% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Belite Bio	N/A	-11.84%	-11.62%

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Bausch Health Cos beats Belite Bio on 10 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to Lantheus?

Bausch Health Cos (NYSE:BHC) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Lantheus has a net margin of 17.69% compared to Bausch Health Cos' net margin of -10.12%. Lantheus' return on equity of 28.10% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Lantheus	17.69%	28.10%	14.35%

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bausch Health Cos presently has a consensus price target of $8.00, indicating a potential upside of 37.81%. Lantheus has a consensus price target of $108.11, indicating a potential upside of 8.15%. Given Bausch Health Cos' higher probable upside, equities analysts clearly believe Bausch Health Cos is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Lantheus had 6 more articles in the media than Bausch Health Cos. MarketBeat recorded 10 mentions for Lantheus and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.38 beat Lantheus' score of 0.23 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has lower revenue, but higher earnings than Bausch Health Cos. Bausch Health Cos is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.21	$157M	-$2.96	N/A
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.14

Bausch Health Cos has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

Summary

Lantheus beats Bausch Health Cos on 11 of the 17 factors compared between the two stocks.

How does Bausch Health Cos compare to Liquidia?

Bausch Health Cos (NYSE:BHC) and Liquidia (NASDAQ:LQDA) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, Liquidia had 27 more articles in the media than Bausch Health Cos. MarketBeat recorded 31 mentions for Liquidia and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.38 beat Liquidia's score of 0.28 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liquidia	7 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral

Bausch Health Cos has higher revenue and earnings than Liquidia. Bausch Health Cos is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.21	$157M	-$2.96	N/A
Liquidia	$158.32M	16.19	-$68.92M	$1.37	20.91

Bausch Health Cos currently has a consensus price target of $8.00, indicating a potential upside of 37.81%. Liquidia has a consensus price target of $83.69, indicating a potential upside of 192.22%. Given Liquidia's stronger consensus rating and higher probable upside, analysts clearly believe Liquidia is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25

Liquidia has a net margin of 30.74% compared to Bausch Health Cos' net margin of -10.12%. Liquidia's return on equity of 149.65% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Liquidia	30.74%	149.65%	36.30%

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by company insiders. Comparatively, 25.6% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bausch Health Cos has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Summary

Liquidia beats Bausch Health Cos on 12 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to Amneal Pharmaceuticals?

Bausch Health Cos (NYSE:BHC) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Bausch Health Cos has higher revenue and earnings than Amneal Pharmaceuticals. Bausch Health Cos is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.21	$157M	-$2.96	N/A
Amneal Pharmaceuticals	$3.02B	2.15	$72.06M	$0.49	41.43

Amneal Pharmaceuticals has a net margin of 5.05% compared to Bausch Health Cos' net margin of -10.12%. Bausch Health Cos' return on equity of -561.95% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bausch Health Cos currently has a consensus target price of $8.00, suggesting a potential upside of 37.81%. Amneal Pharmaceuticals has a consensus target price of $21.00, suggesting a potential upside of 3.45%. Given Bausch Health Cos' higher probable upside, equities research analysts plainly believe Bausch Health Cos is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

In the previous week, Bausch Health Cos had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 4 mentions for Bausch Health Cos and 2 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.51 beat Bausch Health Cos' score of 0.38 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch Health Cos has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks.

How does Bausch Health Cos compare to Definium Therapeutics?

Bausch Health Cos (NYSE:BHC) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Bausch Health Cos has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.21	$157M	-$2.96	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Definium Therapeutics has a net margin of 0.00% compared to Bausch Health Cos' net margin of -10.12%. Definium Therapeutics' return on equity of -84.01% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Definium Therapeutics	N/A	-84.01%	-63.66%

Bausch Health Cos currently has a consensus target price of $8.00, suggesting a potential upside of 37.81%. Definium Therapeutics has a consensus target price of $64.88, suggesting a potential upside of 73.46%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Definium Therapeutics had 16 more articles in the media than Bausch Health Cos. MarketBeat recorded 20 mentions for Definium Therapeutics and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.38 beat Definium Therapeutics' score of 0.32 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Definium Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bausch Health Cos has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market.

Summary

Bausch Health Cos and Definium Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Bausch Health Cos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHC vs. The Competition

Export

Metric	Bausch Health Cos	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.14B	$12.28B	$7.14B	$22.65B
Dividend Yield	N/A	2.64%	2.53%	3.72%
P/E Ratio	-1.96	794.62	273.77	27.75
Price / Sales	0.20	790.44	619.77	20.68
Price / Cash	0.79	82.26	77.60	38.88
Price / Book	5.69	10.46	10.92	4.64
Net Income	$157M	$2.83B	$3.50B	$1.08B
7 Day Performance	1.93%	-1.56%	-2.07%	-1.06%
1 Month Performance	-14.51%	-5.67%	-6.21%	-5.50%
1 Year Performance	-13.16%	-4.72%	7.45%	5.13%

Bausch Health Cos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHC Bausch Health Cos	2.6524 of 5 stars	$5.81 +1.3%	$8.00 +37.8%	-11.4%	$2.14B	$10.85B	N/A	20,300	Analyst Revision
BLTE Belite Bio	3.3175 of 5 stars	$173.40 +1.4%	$218.73 +26.1%	+115.4%	$6.88B	N/A	N/A	41
LNTH Lantheus	3.2165 of 5 stars	$100.28 -0.3%	$108.11 +7.8%	+89.7%	$6.56B	$1.54B	24.22	1,193
LQDA Liquidia	4.105 of 5 stars	$66.43 -0.7%	$98.08 +47.6%	+30.8%	$5.99B	$158.32M	48.49	216	Trending News Analyst Forecast Gap Down
AMRX Amneal Pharmaceuticals	3.1065 of 5 stars	$20.16 +7.7%	$20.14 -0.1%	+95.2%	$5.98B	$3.02B	41.14	8,500	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHC) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch Health Cos (BHC) Competitors

BHC vs. BLTE, LNTH, LQDA, AMRX, and DFTX

How does Bausch Health Cos compare to Belite Bio?

Summary

How does Bausch Health Cos compare to Lantheus?

Summary

How does Bausch Health Cos compare to Liquidia?

Summary

How does Bausch Health Cos compare to Amneal Pharmaceuticals?

Summary

How does Bausch Health Cos compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch Health Cos (BHC) Competitors

BHC vs. BLTE, LNTH, LQDA, AMRX, and DFTX

How does Bausch Health Cos compare to Belite Bio?

Do analysts rate BHC or BLTE?

Does the media prefer BHC or BLTE?

Which has higher earnings & valuation, BHC or BLTE?

Which has more risk & volatility, BHC or BLTE?

Is BHC or BLTE more profitable?

Do insiders & institutionals believe in BHC or BLTE?

Summary

How does Bausch Health Cos compare to Lantheus?

Is BHC or LNTH more profitable?

Do institutionals and insiders believe in BHC or LNTH?

Do analysts recommend BHC or LNTH?

Does the media prefer BHC or LNTH?

Which has preferable valuation & earnings, BHC or LNTH?

Which has more volatility & risk, BHC or LNTH?

Summary

How does Bausch Health Cos compare to Liquidia?

Does the media prefer BHC or LQDA?

Which has stronger valuation and earnings, BHC or LQDA?

Do analysts prefer BHC or LQDA?

Is BHC or LQDA more profitable?

Do institutionals & insiders believe in BHC or LQDA?

Which has more volatility & risk, BHC or LQDA?

Summary

How does Bausch Health Cos compare to Amneal Pharmaceuticals?

Which has better valuation and earnings, BHC or AMRX?

Is BHC or AMRX more profitable?

Do institutionals and insiders have more ownership in BHC or AMRX?

Do analysts rate BHC or AMRX?

Does the media prefer BHC or AMRX?

Which has more volatility and risk, BHC or AMRX?

Summary

How does Bausch Health Cos compare to Definium Therapeutics?

Which has better valuation and earnings, BHC or DFTX?

Is BHC or DFTX more profitable?

Do analysts rate BHC or DFTX?

Do institutionals and insiders have more ownership in BHC or DFTX?

Does the media prefer BHC or DFTX?

Which has more volatility and risk, BHC or DFTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools